Introduction
As a major global public health challenge, the rising prevalence of infertility has garnered considerable attention. Assisted reproductive technology (ART) has brought hope to numerous infertility patients. Since the birth of the first in vitro fertilization (IVF) baby in 1978, ART has become a vital part of the field of modern reproductive medicine. Annually, the number of infants born using these technologies continues to rise. It is estimated that more than 10 million people conceived through ART have come into the world globally [1]. Despite the benefits, the growing demand for ART has raised ongoing concerns about its safety. Although most ART-conceived offspring appear healthy, evidence suggests elevated risks of congenital anomalies, preterm birth (PTB), low birth weight (LBW, < 2500 g), and small for gestational age (SGA, birth weight < 10th percentile) [2]. Among these, LBW and SGA have drawn particular concern. The Developmental Origins of Health and Disease (DOHaD) hypothesis proposes that adverse environmental exposures during early embryonic development can lead to long-term health consequences. These exposures may disrupt germ cell development and placental function through developmental programming, increasing the risk of cardiovascular and metabolic diseases in adulthood [3]. Patient-related factors and ART-related technical interventions can potentially influence fetal development [4]. ART procedures, such as in vitro gamete manipulation and embryo culture, introduce non-physiological conditions. These may impair normal fetal growth via mechanisms such as epigenetic alterations, placental dysfunction, and disrupted embryo–uterine signaling. Given these concerns, close attention to the early growth and developmental outcomes of ART-conceived offspring is urgently needed.
Characteristics of the growth trajectories of ART-conceived offspring
The growth trajectories of ART-conceived offspring have garnered persistent attention. Current research indicates that ART offspring may exhibit distinct growth patterns as early as the prenatal period. Animal models reveal restricted development of the inner cell mass during the implantation stage in ART-derived embryos. However, compensatory placental mechanisms, such as vascular remodeling or volumetric expansion, may normalize birth weight by late gestation [5]. Yet compensatory capacity varies significantly among individuals, with certain ART pregnancies failing to fully offset early developmental deficits, resulting in elevated LBW risks [5]. In human pregnancies, this dynamic compensation exhibits greater heterogeneity. Evidence indicates that embryos in ART pregnancies are smaller in the early stage compared to natural pregnancies, but they show a faster growth rate in the first 3 months of pregnancy [6, 7]. Further subgroup analysis reveals significant differences between transfer protocols: Offspring from frozen-thawed embryo transfer (FET) demonstrate stable accelerated growth from early pregnancy, peaking in the second trimester (19–27 weeks) [8]. In contrast, the fresh embryo transfer (fresh-ET) group shows growth fluctuations, with a larger and faster growth in the early stage compared to the FET group, but a decline in the growth rate in the middle and late pregnancy, resulting in a smaller size at birth [7, 9]. This may be associated with changes in uterine artery pulsatility index (UtA-PI) values throughout gestation and uteroplacental perfusion. Compared with fresh-ET, FET is characterized by higher UtA-PI values, indicating better uteroplacental perfusion [10]. These findings collectively suggest that ART technologies may reprogram fetal growth patterns by altering embryo-maternal communication during critical developmental windows.
Birth weight, as the final product of intrauterine development, holds strong clinical relevance. Evidence indicates that ART-related factors have a more pronounced influence on birth weight than ultrasound-based fetal growth parameters during pregnancy [11]. For example, FET offspring have a significantly higher incidence of large for gestational age (LGA) and macrosomia (≥ 4500 g) compared to both fresh-ET and naturally conceived infants [12], reflecting distinct intrauterine growth trajectories across conception methods. Importantly, birth weight is not only a standardized and accessible clinical measure but also a baseline indicator of postnatal growth and lifelong health. According to the DOHaD hypothesis [3], birth weight predicts future disease risks. High birth weight and LGA are associated with greater risks of childhood hypertension and diabetes [13], while LBW and SGA are linked to increased adult cardiovascular disease risks [14]. Rapid postnatal catch-up growth, especially in the first 3 years, may further elevate risks of childhood obesity, central adiposity, and metabolic syndrome [15].
Despite the central role of birth weight as a bridge between fetal and postnatal health, its determinants in ART offspring remain incompletely understood. Systematically delineating how ART procedural characteristics, maternal infertility pathologies, and intrauterine exposures collectively disrupt intrauterine trajectories to shape birth weight could transcend current monitoring limitations and directly inform clinical ART optimization. This review explores causative pathways spanning maternal infertility etiologies, ART-specific interventions, pregnancy-related disorders, and genetic factors underlying birth weight disparities in ART offspring.
Factors influencing the birth weight of ART offspring
Infertility factors
An increasing number of studies have demonstrated that infertility itself is an important factor contributing to the adverse outcomes of ART offspring. Among these factors, maternal infertility has shown a strong association with birth outcomes, particularly birth weight [4]. Table 1 summarizes the effects of seven common types of maternal infertility on the birth weight of ART offspring.
Table 1.
| Infertility factors | Key pathophysiological features | Impact on birth weight | Proposed mechanisms |
|---|---|---|---|
| Polycystic ovary syndrome [16–21] |
- Hyperandrogenemia - Anovulation - Insulin resistance - Polycystic ovarian morphology |
↑ Risk of FGR, PTB, LBW, and SGA |
- Hyperandrogenemia downregulates placental Slc38a2 transporter, reducing fetal nutrient uptake - Chronic inflammation mediates vascular damage, leading to placental hypoperfusion - Androgen exposure induces abnormal metabolic programming |
| Tubal factor infertility [22–25] |
- Hydrosalpinx/adhesions - Chronic pelvic inflammatory disease - Elevated inflammatory markers (chlamydia IgG, HSP) |
↓ Birth weight ↑ LBW and PTB risks |
- Inflammatory mediators (chlamydia IgG/HSP) induce placental dysfunction - pelvic inflammatory disease-associated preterm labor: Inflammation triggers uterine contractions |
| Endometriosis [26–28] |
- Uterine dysfunction (impaired embryo implantation and decidualization) - Inflammatory cytokine interference |
Inconclusive evidence; potential ↑ LBW, SGA, and PTB |
- Inflammatory microenvironment: Cytokines suppress placental angiogenesis - Reduced uterine receptivity: Lesions disrupt embryo implantation and trophoblast invasion - Oocyte quality decline ↑ aneuploidy risk |
| Adenomyosis [29–34] |
- Disrupted uterine junctional zone - Chronic oxidative stress and inflammation - Decidualization anomalies/uterine contractility dysfunction |
↑ LBW, SGA, and PTB |
- Uterine blood flow disruption: Spiral artery abnormalities → placental hypoperfusion - Oxidative stress damage: ROS↑ → trophoblast invasion defects - Abnormal contractions: Luteal-phase uterine peristalsis → placental displacement |
| Uterine fibroids [35–39] |
- Mechanical uterine compression - Placental blood flow obstruction - Oxidative supply fluctuations due to contractile anomalies |
↑ LBW, SGA, and FGR |
- Vascular compression: Fibroid-induced ischemia/hypoxia - Uterine cavity distortion: Limits fetal growth space - Pro-inflammatory cytokines: Impair placental development |
| Fetal ovarian cysts [40, 41] |
- Elevated fetal estrogen/HCG levels - Structural divergence (simple vs. complex cysts) - High complication risk (torsion/rupture) |
↓ Birth weight in complex fetal ovarian cysts; potential ↑ FGR |
- Mechanical compression: Large cysts restrict fetal organ/vascular development - Ischemic complications: Torsion/rupture → fetal stress - Hormonal interference: Maternal hyperestrogenemia disrupts placental-fetal axis |
| Diminished ovarian reserve [43–47] |
- Reduced oocyte quantity/quality - Age-dependent hormonal dysregulation (AMH↓, FSH↑) |
Controversial independent risk; advanced age and aneuploidy may indirectly reduce birth weight |
- Oocyte quality defects: Aneuploid embryos with impaired developmental potential - Synergistic aging effect: LBW risk compounded with age - Hormonal imbalance: AMH/FSH dysregulation impairs endometrial receptivity |
This table synthesizes evidence on how maternal infertility factors contribute to adverse birth weight outcomes in ART offspring through distinct pathophysiological pathways. Adapted from referenced studies with standardized abbreviations. Symbols: ↓ indicates reduction; ↑ indicates increased risk. FGR fetal growth restriction, LBW low birth weight, SGA small for gestational age, PTB preterm birth, HCG human chorionic gonadotropin, AMH anti-Müllerian hormone, FSH follicle-stimulating hormone, HSP heat shock protein, ROS reactive oxygen species
Polycystic ovary syndrome (PCOS)
PCOS is the most common endocrine disorder in women of reproductive age. It is characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology, often accompanied by insulin resistance. Although ART has improved fertility outcomes in women with PCOS, the underlying pathophysiological features of the disorder predispose both mothers and offspring to pregnancy and delivery complications. A recent meta-analysis of 73 studies reported that, in the general population, the offspring of women with PCOS had significantly lower average birth weight (− 56.02 g; 95% CI − 97.87 to − 14.16) compared to the offspring of women without PCOS. Additionally, increased risks of PTB (odds ratio [OR] = 1.53; 95% CI 1.33–1.75), fetal growth restriction (FGR) (OR = 1.84; 95% CI 1.09–3.10), LBW (OR = 1.28; 95% CI 1.04–1.59), and SGA (OR = 1.11; 95% CI 0.87–1.41) were observed [16]. In a large clinical cohort, Aaserud et al. compared 390 women with PCOS to 68,708 controls. Offspring of PCOS mothers had significantly lower birth weight (− 0.26 standard deviations [SD]; 95% CI − 0.38 to − 0.14), shorter birth length (− 0.19 SD; 95% CI − 0.33 to − 0.05), and smaller head circumference (− 0.13 SD; 95% CI − 0.26 to − 0.01). Placental weight was also reduced by an average of 24 g (95% CI − 43 to − 5) [17].
Hyperandrogenemia, a hallmark of PCOS, is closely linked to FGR. Animal models show that prenatal androgen exposure activates the hypothalamic-pituitary-ovarian axis, leading to intrauterine growth retardation, metabolic dysfunction, and features of PCOS in offspring [18]. Excess fetal androgen also induces placental vascular abnormalities, reduces uteroplacental blood flow, and causes hypoxia, thereby compromising fetal growth [19]. Clinical studies support these mechanisms: hyperandrogenemia impairs placental function by downregulating amino acid transporters such as Slc38a2/Snat2, limiting fetal nutrient supply [20]. Moreover, chronic low-grade inflammation in PCOS may contribute to vascular injury and placental hypoperfusion [21], further exacerbating growth restriction and reducing birth weight.
Tubal factor infertility
Tubal pathology is a leading cause of female infertility. One common manifestation is hydrosalpinx, characterized by fluid accumulation in the fallopian tubes, which significantly reduces pregnancy rates in IVF and increases the risk of miscarriage. A large cross-sectional study (n = 11,418,774) using data from the US ART Surveillance System found that ART cycles involving tubal factor infertility were associated with higher risks of PTB (15.8% vs. 11.6%; adjusted relative risk [aRR] = 1.27; 95% CI 1.20–1.34) and LBW (10.9% vs. 8.5%; aRR = 1.28; 95% CI 1.20–1.36), compared to cycles linked to male factor infertility [22]. Similarly, a UK-based study analyzing all ART cycles (n = 117,401) reported increased risks of PTB (adjusted odds ratio [aOR] = 1.25; 99.5% CI 1.14–1.38) and LBW (aOR = 1.12; 99.5% CI 1.02–1.23) in cases involving tubal factor infertility, compared to other causes of infertility [23]. These risks may be linked to specific etiologies. For instance, pelvic infections are a major contributor to tubal damage. A population-based cohort study confirmed that women with a history of pelvic infection had a significantly higher risk of PTB than those without such a history [24]. Mechanistically, chronic inflammation, which is evidenced by elevated chlamydia IgG titers and heat shock protein levels, has been associated with pelvic infection–induced tubal pathology and adverse pregnancy outcomes [25]. This persistent inflammatory state may compromise uterine and placental function, leading to PTB and reduced birth weight. Therefore, tubal pathology not only contributes to infertility but also increases the risk of adverse birth weight in ART-conceived pregnancies.
Endometriosis
Endometriosis is a prevalent cause of infertility, characterized by the presence of endometrial tissue outside the uterine cavity. It impairs fertility through several mechanisms, including disrupted ovulation, impaired oocyte quality, increased inflammatory cells in peritoneal fluid, and the formation of ovarian endometriomas. Structural alterations of the endometrium further compromise the uterine environment, potentially affecting embryo implantation and early development. These disruptions can persist throughout pregnancy, leading to adverse maternal and fetal outcomes.
A study by Farland et al. reported an increased risk of LBW in pregnancies among women with endometriosis, with an absolute risk of 5.6% (RR = 1.16; 95% CI 1.03–1.29) [26]. This risk was particularly pronounced in second or later pregnancies, possibly due to cumulative impairment of uterine and placental function. A meta-analysis also identified elevated risks of PTB (OR = 1.70; 95% CI 1.40–2.06) and SGA infants (OR = 1.28; 95% CI 1.11–1.49) in women with endometriosis [27]. However, not all studies have confirmed these associations. Some report adverse pregnancy outcomes in women with endometriosis but fail to find significant increases in LBW or SGA rates [28]. These inconsistencies highlight the need for larger, well-controlled cohort studies and improved diagnostic criteria to clarify the relationship between endometriosis and birth weight.
Adenomyosis
Adenomyosis is defined by the ectopic presence of endometrial glands and stroma within the myometrium. Its estimated prevalence ranges from 20 to 35%. This heterogeneous disorder is present across a wide spectrum. Uterine size may remain normal or become markedly enlarged. Clinically, it ranges from asymptomatic cases to severe dysmenorrhea and menorrhagia. It often coexists with endometriosis [29]. A pooled analysis of two meta-analyses by Nirgianakis et al. reported a significantly increased risk of LBW in women with adenomyosis (pooled OR = 2.82; 95% CI 1.20–6.62) [30]. Other recent meta-analyses found similarly elevated risks for SGA infants, with pooled ORs ranging from 2.86 to 3.90 [29]. Notably, adverse outcomes appear to be exacerbated when adenomyosis coexists with ART. A study by Shin et al. compared pregnancies conceived via ART versus natural conception among women with adenomyosis. They observed significantly higher rates of PTB (28.0% vs. 4.3%, P < 0.01) and LBW (28.0% vs. 6.4%, P < 0.05) in the ART subgroup [31]. In contrast, no significant differences in PTB or LBW were found between conception methods among women without adenomyosis.
Several mechanisms may explain these associations. First, adenomyosis disrupts the uterine junctional zone, leading to abnormal myometrial contractility during the luteal phase. These dysfunctional contractions reduce endometrial receptivity and may hinder embryonic development [32]. Second, the condition increases intrauterine oxidative stress, which can cause maternal endothelial dysfunction. This results in spiral artery remodeling, increased uterine artery resistance, and impaired placental perfusion, all of which contribute to FGR [33]. Third, adenomyosis alters the inflammatory profile of the decidualized myometrium. Heightened local inflammation may impair trophoblast invasion at the JZ, destabilizing placentation and fetal support [34].
Uterine fibroids
Uterine fibroids (leiomyomas) are benign tumors that develop within or on the uterine wall. They are frequently associated with pelvic pain, abnormal bleeding, and a range of adverse reproductive outcomes. These include infertility, miscarriage, PTB, postpartum hemorrhage, placental malposition, FGR, and LBW [35]. A population-based cohort study by Harlev et al. found independent associations between the presence of fibroids during pregnancy and increased risks of FGR, LBW, and SGA infants [36]. Similarly, Egbe et al. reported an LBW rate of 13.6% in fibroid-affected pregnancies, compared to 4.5% in unaffected controls [37]. A recent meta-analysis confirmed a higher incidence of LBW in pregnancies complicated by fibroids (11.53%) versus non-fibroid pregnancies (10.40%), with a pooled relative risk (RR) of 1.72 (95% CI 1.03–2.85; P < 0.001) [38].
Multiple mechanisms have been proposed to explain these outcomes. First, fibroids may mechanically compress adjacent uterine vasculature. This can impair placental perfusion and directly contribute to FGR [38]. Second, fibroids can alter uterine contractility, which may disrupt oxygen and nutrient delivery to the fetus [39]. These structural and functional abnormalities highlight the complex role of fibroids in compromising fetal development and regulating birth weight.
Fetal ovarian cysts (FOCs)
FOCs are the most common abdominal tumors identified during the fetal period. Ultrasound findings typically classify them as either simple or complex cysts. A widely accepted hypothesis suggests that FOCs arise from hormonal stimulation, including elevated levels of maternal estrogens, fetal gonadotropins, and placental human chorionic gonadotropin [40]. The impact of FOCs on neonatal birth weight appears to depend on cyst size, anatomical location, and associated complications such as torsion or rupture. In a study of 20 cases, neonates with complex FOCs had significantly lower birth weights (3080 ± 141.76 g) than those with simple cysts [41]. Complex cysts are usually larger and more likely to cause complications, which may disrupt intrauterine growth. Mechanisms include mechanical compression of fetal structures and ischemic damage due to torsion, both of which can impair placental function and compromise fetal nutrient and oxygen delivery. These disruptions may lead to intrauterine growth restriction and reduced birth weight.
Diminished ovarian reserve (DOR)
Ovarian reserve is a critical indicator of a woman’s fertility, reflecting both the number and quality of oocytes in the ovaries. Advancing maternal age is commonly associated with DOR, which negatively impacts pregnancy outcomes in IVF [42]. Abdullah et al. classified participants into four groups according to the POSEIDON (Patient-Oriented Strategies Encompassing Individualized Oocyte Number) criteria for ovarian reserve. Their findings revealed that women aged 35 and above with DOR in POSEIDON group 4 had the highest prevalence of LBW, at 11.7%, significantly higher than other groups (P < 0.001) [43]. However, DOR alone does not seem to significantly increase the risk of LBW in younger populations [44]. A recent retrospective cohort study found no direct link between DOR and LBW [45], suggesting that DOR may not independently affect fetal growth but may interact with other factors.
DOR is associated with reduced oocyte quality and a higher risk of embryonic aneuploidy. Aneuploid embryos, characterized by chromosomal abnormalities, have compromised developmental potential. Even if successfully implanted, these embryos are more likely to result in early pregnancy loss, congenital anomalies, or affect birth weight indirectly [46]. Additionally, advanced maternal age, a major factor contributing to DOR, is itself an independent risk factor for LBW [43]. In older women, DOR may amplify this risk. Hormonal changes related to DOR, such as decreased anti-Müllerian hormone (AMH) and elevated follicle-stimulating hormone (FSH) levels, can disrupt the intrauterine environment. These disturbances could potentially influence fetal growth and birth weight [47].
ART treatment
Currently, ART has evolved through three generations, encompassing core techniques such as IVF combined with embryo transfer, intracytoplasmic sperm injection (ICSI), embryo biopsy, and preimplantation genetic testing (PGT). ART is a complex, multi-step process that includes controlled ovarian stimulation (COS), oocyte retrieval, in vitro embryo culture, embryo cryopreservation/thawing, endometrial preparation, and embryo transfer, as shown in Fig. 1. The placenta, often referred to as the “life tree” of fetal development, regulates nutrient delivery, endocrine functions, and immune homeostasis through its villous vascular network [48]. However, ART procedures can disrupt this delicate system, leading to placental dysfunction. For example, hormonal stimulation and embryo transfer have been linked to placental morphological abnormalities, such as placenta membranacea and circumvallate placenta, as well as angiogenic defects [49]. These issues can result in reduced villous branching, inadequate spiral artery remodeling, and subsequent placental hypoperfusion and oxygenation deficits. These mechanisms may contribute to the impact of ART on offspring birth weight. Table 2 summarizes the effects of each ART step on birth weight and the potential underlying mechanisms of aberrant birth weight in ART-conceived offspring.
Table 2.
| ART factor | Potential mechanisms/pathways | Main findings | Association with birth weight |
|---|---|---|---|
| Controlled ovarian stimulation [50–54] | Supraphysiological E2 levels inhibit trophoblast invasion → abnormal placental blood flow; reduced endometrial receptivity |
- Each ↑100 pg/mL in E2 peak associated with ↓5.0 g birth weight (P = 0.038) - E2 > 3000 pg/mL: ↑LBW (OR = 2.32), ↑SGA (OR = 2.44) |
Elevated E2 levels → ↑LBW/SGA risk, ↓birth weight |
| Transfer cycle type [55–58] | High E2 in fresh-ET cycles induces endometrial vascular dysfunction; FET restores physiological hormone exposure or selects high-quality embryos |
- FET vs. fresh-ET: ↓LBW (RR = 0.72), ↓SGA (RR = 0.61); ↑LGA (AOR = 1.70) - Multi-embryo FET group ↑birth weight |
FET reduces LBW risk, but ↑LGA risk |
| Endometrial preparation protocol for FET [63–68] | Absence of corpus luteum in HRT cycles → impaired placental development, vascular remodeling, and hormonal signaling (e.g., relaxin deficiency); exogenous hormonal imbalance in HRT → mismatched endometrial-embryo synchrony or placental dysfunction |
- HRT cycles: ↑macrosomia (7.4% vs. 4.6% in natural cycles) - HRT ↑LGA risk (aOR = 1.36, P = 0.003) - HRT ↑LBW (aOR = 1.78) - PTB/VPTB |
HRT → ↑LGA/macrosomia (likely via vascular overperfusion) and ↑LBW (via placental insufficiency) - Dual-directional impact on birth weight: ↑risk of extremes (SGA/LGA) |
| Pre-transfer endometrial thickness [69–72] | Thin endometrium (< 7.5–8 mm) → increased oxygen tension/impaired spiral artery remodeling → placental hypoperfusion |
- EMT < 8 mm → ↑LBW risk (aOR = 1.57), ↑PTB (aOR = 1.68) - EMT ≤ 7.5 mm: ↑LBW (aOR = 2.18), ↑SGA (aOR = 2.39) - Meta-analysis: EMT < 8 mm → ↑LBW (OR = 1.84) ↓birth weight (MD = − 78.88 g) |
↓EMT → ↑LBW/SGA/PTB risk |
| Embryo stage at transfer [75–77] | Blastocyst culture triggers epigenetic alterations; better embryo selection → fetal overgrowth |
- Blastocyst vs. cleavage stage: ↓LBW (aRR = 0.92), ↓SGA (aRR = 0.83); ↑LGA (aRR = 1.57) - ↑Spontaneous PTB risk (4.6% vs. 2.0%; P = 0.02) |
Blastocyst transfer ↓SGA risk but ↑LGA/PTB risk |
| Number of embryos transferred [79–82] | Multiplicity in gestation → uterine overdistension/placental resource competition → fetal growth restriction |
- Transferring ≥ 2 embryos → ↑multiple pregnancy rate → ↑PTB/LBW risk - e-SET ↑birth weight by 297.47 g, ↓LBW risk (aRR = 0.20) - DET vs. e-SET: ↑LBW risk in singletons (OR = 1.64; aOR = 1.83) |
DET ↑LBW/PTB risk; e-SET improves birth weight outcomes |
| Embryo quality [84–86] | High-quality embryos exhibit greater growth potential; poor-quality embryos → placental dysfunction |
- High-quality blastocysts: ↑birth weight by 183.5 g (95% CI − 295.1 to − 71.9 g, P = 0.001) - Low-quality blastocysts (TE = C) → ↑LBW risk |
↑Embryo quality → improved birth weight; ↓quality ↑LBW risk |
| Embryo biopsy [87–90] | Mechanical damage or epigenetic disruption from biopsy → reduced developmental potential; chromosomal screening optimizes genetic quality |
- PGT group vs. non-PGT: ↓LBW, VLBW, VPTB - Cleavage-stage biopsy → ↑LBW/SGA risk - Overall risk remains controversial |
PGT may ↓LBW risk, but procedural risks are debated |
| Embryo culture medium [91–96] | Variable components alter epigenetics (e.g., H19/Igf2 methylation) → impaired/excessive placental nutrient transport |
- G1-PLUS medium → ↑LGA/macrosomia; Vitrolife vs. Cook → ↑birth weight - HTF vs. G5 medium → ↓birth weight - Prolonged storage → ↓birth weight (β = − 3.6 g/day) - Single-step medium → ↑LGA risk (aOR = 2.1) |
Medium composition/storage duration → birth weight fluctuations |
This table synthesizes evidence on how ART factors contribute to adverse birth weight outcomes in ART offspring through distinct pathophysiological pathways. Adapted from referenced studies with standardized abbreviations. Symbols: ↓ indicates reduction; ↑ indicates increased risk. ART assisted reproductive technology, LBW low birth weight (< 2500 g), SGA small for gestational age, LGA large for gestational age, PTB preterm birth (< 37 weeks), VLBW very low birth weight (< 1500 g), VPTB very preterm birth (< 32 weeks), E2 estradiol, FET frozen embryo transfer, fresh-ET fresh embryo transfer, HRT hormone replacement therapy, e-SET elective single-embryo transfer, DET double-embryo transfer, EMT endometrial thickness, PGT preimplantation genetic testing, TE trophectoderm grade
Controlled ovarian stimulation
COS involves the administration of exogenous gonadotropins (Gn) to either simulate or override endogenous hormonal activity, promoting the synchronized development and maturation of multiple ovarian follicles. As a key step in ART, COS is associated with elevated estradiol (E2) levels, which correlate with the number and size of developing follicles. While recruiting additional follicles generally correlates with enhanced pregnancy chances for infertility patients, observational studies indicate that supraphysiological E2 levels may be linked to impaired post-transfer implantation success and placental development, potentially contributing to adverse pregnancy outcomes, including reduced birth weight. A single-center retrospective cohort study found that serum E2 levels during COS cycles were significantly higher than in natural cycles. These elevated levels potentially alter the endometrial environment, increasing the risks of hypertensive disorders, LBW, and placental abnormalities [50]. Zhang et al. compared neonatal outcomes between natural cycle IVF and ovarian stimulation IVF in a retrospective cohort and found that each 100 pg/mL increase in peak E2 concentration was associated with a 5.0 g decrease in birth weight (P = 0.038) [51]. Similarly, Cai et al. reported that patients with elevated E2 levels (> 3000 pg/mL) had significantly higher risks of LBW (OR = 2.32, 95% CI 1.01–5.40) and SGA neonates (OR = 2.44, 95% CI 1.37–4.34) in single full-term infants. They also observed a negative correlation between E2 levels and birth weight [52].
Under physiological conditions, estrogen and progesterone work together to regulate key reproductive processes, such as gamete maturation, embryonic development, and placental formation. However, surpassing physiological hormone thresholds can lead to adverse pregnancy outcomes. Supraphysiological E2 exposure during early gestation, for instance, inhibits trophoblast invasiveness and disrupts uterine spiral artery remodeling. This dysregulation may result in placental hemodynamic abnormalities, inadequate placental perfusion, and FGR [53]. Additionally, elevated estrogen and progesterone levels, especially when their balance is disrupted, induce morphological changes in the endometrium, including reduced endometrial volume, a decreased endometrial-to-myometrial thickness ratio, and abnormal uterine cavity morphology. Endometrial vascular dilation and abnormal vascular density are also observed. Such changes have been mechanistically linked to impaired receptivity, compromised embryo implantation, and diminished developmental potential [54].
Embryo transfer cycle types
Embryo transfer cycles are generally classified into fresh-ET and FET based on the preservation status of the embryos. In recent years, the use of FET has steadily increased, as cryopreservation technologies have become a standard component of ART protocols. Many reproductive centers now advocate a “freeze-all” strategy, although its safety remains a subject of debate. Studies comparing neonatal outcomes between FET-conceived and fresh-ET-conceived infants report similar or even improved clinical outcomes for FET, particularly regarding the risks of LBW, SGA, and PTB [4]. However, other studies suggest higher risks of macrosomia and LGA in FET-conceived singletons compared to fresh-ET. A cumulative meta-analysis of 26 studies found that FET-conceived singletons had reduced relative risks for PTB (RR = 0.90; 95% CI 0.84–0.97), LBW (RR = 0.72; 95% CI 0.67–0.77), and SGA (RR = 0.61; 95% CI 0.56–0.67) compared to fresh-ET counterparts [55]. A US cohort study of ART-conceived singletons born between 2004 and 2013 also revealed that FET-conceived siblings had higher birth weights and significantly increased risks for LGA (aOR = 1.70; 95% CI 1.46–1.98 for fresh-ET vs. FET) [56]. Similar trends were observed in twin pregnancies. A retrospective cohort study of 773 IVF-conceived twins by Shavit et al. reported higher mean birth weight and lower incidences of SGA, LBW, and very low birth weight (VLBW) in the FET group [57]. A recent Nordic cohort study of 4,606,875 neonates confirmed that FET-conceived infants had higher birth weights, increased LGA likelihood, and reduced odds of SGA compared to fresh-ET, while both transfer types were associated with elevated PTB risks compared to spontaneously conceived pregnancies [58].
The mechanisms underlying these outcomes remain unclear, but are gradually becoming clear. Some researchers suggest that the advantages of FET may stem from the avoidance of ovarian hyperstimulation during fresh-ET cycles, where supraphysiological estrogen levels can impair endometrial angiogenesis and placental development [59]. Supporting this view, longitudinal UtA Doppler studies reveal optimized uteroplacental hemodynamics in FET cycles: Cavoretto et al. documented a 14% reduction in mean UtA-PI throughout gestation (7–37 weeks) in FET pregnancies versus fresh-ET (P < 0.001), directly linking improved placental perfusion to reduced SGA risk [10]. This hemodynamic improvement likely reflects FET’s capacity to bypass hyperestrogenemia-induced disruptions to endometrial vascular remodeling, thereby enhancing early growth stability. Whereas during the FET cycle, the uterine environment is considered more physiologic, as the effects of prior ovarian hormonal stimulation typically dissipate by the time of embryo transfer [60, 61]. Additionally, an alternative hypothesis suggests that the freeze–thaw process may selectively preserve higher quality embryos, thereby enhancing fetal growth potential [62].
Endometrial preparation protocols prior to FET
Endometrial preparation protocols for FET primarily include natural ovulatory cycles, stimulated cycles, and hormone replacement therapy (HRT) cycles. Among these, HRT has become the most widely used method due to its flexibility, minimal cycle monitoring requirements, ease of scheduling, absence of injectable medications, and applicability to anovulatory women. While many studies attribute the increased risk of LGA in offspring conceived through FET to epigenetic changes caused by cryopreservation, some research suggests that HRT may have a more direct and significant impact than the cryopreservation process itself. A large-scale cohort study by Ginström Ernstad et al. (n = 1,161,657) found significantly higher incidences of macrosomia associated with HRT cycles (7.4%) compared to natural (4.6%) and stimulated cycles (5.2%) [63]. Hesters et al. also identified elevated risks of LGA in HRT cycles (aOR = 1.36, 95% CI 1.11–1.67, P = 0.003) [64]. Similarly, Wang et al. confirmed increased incidences of LGA and macrosomia in HRT cycles compared to other protocols [65]. However, two population-based studies from China have reported contradictory results, indicating that HRT protocols might be associated with an increased risk of LBW, with an aOR of 1.78 (95% CI 1.39–2.28) [66]. These studies also observed higher incidences of PTB and very preterm birth (VPTB) [67].
The mechanisms potentially underlying the observed associations between HRT and birth weight remain unclear. The contradictory findings of increased risks for both LBW and LGA could potentially be explained by the following hypotheses: In HRT protocols, exogenous estradiol and progesterone are used for endometrial preparation, which suppresses the normal ovulation process and results in the absence of the corpus luteum (CL). Since hormones like estradiol, progesterone, and relaxin, produced by the CL, play a key role in embryo implantation, placental formation, and vascular remodeling, their absence could have two opposing effects. On one hand, the lack of these hormones may impair vascular health, leading to elevated blood pressure. This, in turn, could increase uteroplacental blood flow, indirectly promoting excessive fetal growth and contributing to the observed increased risk of LGA [67, 68]. On the other hand, the absence of the CL may impair placental function. Combined with the inability of exogenous hormones used in HRT to fully replicate the hormonal environment of a natural cycle, this could potentially lead to abnormal placental development and restricted fetal growth [66].
Endometrial thickness prior to embryo transfer
The thickness of the endometrium (EMT), a key determinant of endometrial receptivity, may be associated with embryo implantation success and perinatal outcomes, including abnormal birth weight. Observational studies indicate that when EMT is thin (typically defined as < 8 mm), the risk of complications increases. Studies show that women with EMT < 8 mm are at a significantly higher risk of delivering LBW infants (aOR = 1.57, 95% CI 1.09–2.26) [69] and face an independently increased risk of PTB (aOR = 1.68, 95% CI 1.12–2.52) [70]. When EMT ≤ 7.5 mm, the risk of LBW further increases (aOR = 2.179, 95% CI 1.305–3.640) [71], and the likelihood of delivering SGA infants doubles (aOR = 2.391, 95% CI 1.155–4.950) [72]. Recent meta-analyses confirm these associations, reporting that thin endometrium (< 8 mm) is associated with a raised incidence of LBW (OR = 1.84, 95% CI 1.52–2.22) and SGA (OR = 1.41, 95% CI 1.17–1.70), as well as reduced neonatal birth weight (MD = − 78.88 g, 95% CI − 115.79 to − 41.98).
The underlying mechanisms may involve several factors: First, a thin endometrium might cause the embryo to implant closer to the basal endometrium. Compensatory angiogenesis in this area can increase local blood flow, leading to a hyperoxic environment. This, in turn, elevates oxidative stress and may harm the embryo. Second, a thin endometrium is often associated with increased resistance in the uterine radial arteries and impaired remodeling of the spiral arteries. The expression of key angiogenic factors, such as vascular endothelial growth factor (VEGF) and leukemia inhibitory factor (LIF), is also reduced. These factors contribute to poor vascular development and insufficient overall blood flow, which may fail to meet the placenta’s normal blood supply needs in later stages, potentially thereby affecting fetal growth [73, 74].
Embryo manipulation
Embryo transfer type
Blastocyst transfer, which involves extending embryo culture to the blastocyst stage (days 5–6), has become a prominent strategy in modern IVF and ICSI protocols. Compared to traditional cleavage-stage (days 2–3) embryo transfer, blastocyst culture offers advantages in embryo selection and endometrial-embryo synchrony, which improves live birth rates per transfer. However, emerging evidence highlights the potential adverse perinatal outcomes associated with this approach. A large population-based study including 86,630 singleton, 43,886 twin, and 5384 sibling singleton births showed that blastocyst transfer was associated with reduced risks of LBW (aRR = 0.92; 95% CI 0.86–0.99) and SGA (aRR = 0.83; 95% CI 0.78–0.89) in singletons compared to cleavage-stage transfers. However, it was also associated with a significantly increased risk of LGA infants (aRR = 1.57; 95% CI 1.01–2.46) [75]. These results align with a meta-analysis of 35 studies, which confirmed that blastocyst transfer is an independent risk factor for LGA [76]. While the changes in LBW and VLBW were not significant, the increased risk of spontaneous PTB associated with blastocyst transfer should not be overlooked [75–77]. PTB can still lead to lower birth weights in some fetuses.
Although prolonged culture may enhance embryo viability, potential media-triggered epigenetic changes could contribute to excessive fetal growth [78]. The observed associations of blastocyst transfer with risks of LGA, which are linked to childhood obesity and metabolic syndrome, and PTB warrant cautious consideration, despite the method’s efficacy in improving implantation.
Number of embryos transferred
Multiple pregnancies, a significant complication of ART, are associated with adverse effects on fetal growth through various pathophysiological pathways. Transferring two or more embryos greatly increases the risk of multiple gestation, which leads to uterine overdistension, increased intrauterine pressure, and abnormal placental blood flow distribution. These factors are linked to heightened risks of PTB and FGR [79]. This “dual physiological dilemma” stems from increased maternal nutritional demands and competition for resources between placentas, potentially contributing to elevated risks of LBW and SGA neonates.
To reduce these risks, elective single-embryo transfer (e-SET) has become the standard practice in advanced ART centers. A meta-analysis of 85 studies showed that e-SET was associated with increased neonatal birth weight by 297.47 g (95% CI 208.47–386.46 g) and an 80% reduction in LBW risk (aRR = 0.20; 95% CI 0.16–0.25) compared to double-embryo transfer (DET) [80]. A large Swedish cohort study found that even in singleton live births, DET significantly increased PTB and LBW risks compared to e-SET. Specifically, DET during FET cycles raised singleton LBW risk (OR = 1.64; 95% CI 1.19–2.25), and blastocyst-stage DET raised LBW risk even more significantly (aOR = 1.83; 95% CI 1.29–2.60) [81]. Similar trends were observed in fresh embryo transfers in a large cohort study in the UK [82]. Notably, Li’s team highlighted that “vanishing twin” syndrome after DET might trigger chronic intrauterine inflammation due to necrotic placental tissue, potentially impairing uteroplacental perfusion and exacerbating FGR-related birth weight deficits [83].
Embryo quality
Embryo quality assessment is a critical factor in ART success, primarily relying on morphological evaluation through optical microscopy, which remains the standard for clinical assessment. Substantial evidence supports a positive correlation between good-quality embryos and favorable perinatal outcomes. Zhang et al. demonstrated that neonates from high-quality blastocyst transfers had significantly higher birth weights compared to those from low-quality embryos (+ 183.5 g; 95% CI − 295.1 to − 71.9 g, P < 0.01) [84]. Similarly, Shi et al., in a cohort of 1301 fresh single-blastocyst transfer cycles, observed that high-grade blastocysts (AA-grade) improved birth weight outcomes. In contrast, transfers of average- and poor-quality blastocysts, especially those with C-grade trophectoderm (TE), were associated with increased LBW risks in singleton pregnancies [85].
Further supporting these findings, Huang et al. reported that, in single-embryo transfer cycles, compared to high-quality embryos, suboptimal embryo quality from either cleavage- or blastocyst-stage transfers significantly increased the risk of LBW [86]. These results highlight the pivotal role of embryological grading systems in predicting intrauterine growth dynamics and birth weight outcomes.
Preimplantation genetic testing and embryo biopsy
PGT, the third-generation ART technique, involves the genetic analysis of trophoblast cells obtained through embryo biopsy at a specific developmental stage. It is commonly used to test for monogenic diseases (PGT-M), structural rearrangements (PGT-SR), and aneuploidies (PGT-A) in embryos produced during IVF/ICSI cycles. However, the biopsy procedure, whether involving mechanical disruption or epigenetic perturbations, may impair developmental competence, raising concerns about its clinical safety.
Early observational studies generally reported comparable neonatal outcomes between PGT and conventional IVF/ICSI pregnancies [87]. More recent meta-analyses suggest nuanced risks. PGT has been associated with reduced risks of LBW, VLBW, and VPTB compared to non-biopsied ART cycles. However, PGT-conceived offspring still exhibit higher LBW and PTB rates than naturally conceived infants [88, 89]. Notably, a qualitative analysis of 31 studies found that cleavage-stage embryo biopsies may be associated with higher risks of LBW and SGA compared to non-biopsied embryos [90]. Overall, PGT remains one of the most contentious procedures in reproductive medicine, with ongoing uncertainties regarding its long-term neonatal safety [90].
Embryo culture media
Embryo culture media, which provide the critical microenvironment for in vitro development, can influence birth weight outcomes through variations in composition, storage duration, and culture strategies. Studies show that different media types lead to varying birth weight outcomes. For example, G1-PLUS v5 media supplemented with human serum albumin (HSA) are associated with higher birth weight z-scores and increased rates of LGA infants and macrosomia compared to basal G1 v5 formulations [91]. Similarly, neonates from Vitrolife media tend to exhibit significantly higher birth weights than those from Cook media [92], while blastocysts cultured in human tubal fluid (HTF) media tend to have lower birth weights compared to those cultured in G5 media [93].
Prolonged media storage can also compromise embryonic potential due to chemical degradation (e.g., amino acid oxidation), potentially contributing to adverse birth weight outcomes. Kleijkers et al. quantified the impact of storage duration by subtracting production dates from oocyte retrieval dates. They found a negative correlation between birth weight and media age (β = − 3.6 g per day; SE, 1.5 g; P = 0.021), with a 65-day storage difference leading to a 234 g reduction in birth weight [94].
Cultural system models are another important factor. Single-step media, where embryos “select” the essential components according to their needs, are associated with increased LGA risks (aOR = 2.1; 95% CI 1.04–4.22; P = 0.038) compared to sequential media systems designed to mimic in vivo embryo culture conditions [95]. Animal studies suggest that media components may disrupt placental imprinting genes (e.g., H19, Igf2) by altering DNA methylation levels, which could potentially impair nutrient transfer and contribute to abnormal birth weight outcomes [96]. These findings underscore the importance of optimizing culture media protocols.
Intrauterine exposure factors: pregnancy-related disorders
During the latter half of gestation, various intrauterine exposure factors, including maternal, pregnancy-related, and environmental factors, can influence fetal growth. ART, in particular, may alter the intrauterine growth environment, potentially increasing the risk of maternal complications such as gestational hypertension, gestational diabetes, and gestational thyroid diseases. The interaction between the intrauterine environment and maternal complications can further impact fetal birth weight [97].
Hypertensive disorders of pregnancy (HDP)
ART pregnancies are linked to elevated risks of gestational hypertension and preeclampsia (PE), both of which can significantly affect birth weight. A prospective case–control study indicated that neonates of hypertensive mothers had notably lower birth weights, body lengths, abdominal circumferences, and head circumferences compared to normotensive controls (P = 0.001) [98]. A recent large-scale cohort study further revealed that hypertensive mothers had higher risks of delivering LGA and macrosomia (aOR 1.29–1.91) and LBW neonates (aOR 1.23–3.56) [99]. Stratification by disease severity indicated that mild hypertension was primarily associated with macrosomia/LGA (aOR 1.25–1.32), while severe hypertension and PE/eclampsia were linked to LBW and SGA outcomes (aOR 1.27–2.77) [99]. Notably, HDP mediates 20.7% of the elevated PTB risk in FET pregnancies compared to natural conception (OR = 1.05, 95% CI 1.04–1.05), while this association was not observed in fresh-ET [100]. Differences in ART techniques, along with HDP, may jointly affect offspring birth outcomes.
Placental insufficiency is the primary mechanism linking HDP and LBW. Hypertension-induced vasospasm and vascular endothelial dysfunction reduce uteroplacental perfusion, leading to hypoxia, toxic factor release, and trophoblast apoptosis. These processes impair placental development and nutrient transport, ultimately restricting fetal growth [49]. Additionally, HDP may affect neonatal leukocyte telomere length (LTL) through adverse intrauterine environments. Elevated LGA risk in hypertensive pregnancies is correlated with altered LTLs, suggesting the role of epigenetic modifications in fetal growth pathways [101].
Gestational diabetes mellitus (GDM)
The population undergoing ART is at increased risk for developing GDM [102], which disrupts fetal growth through various metabolic pathways. A recent meta-analysis showed that GDM significantly elevates the risks for LGA infants (RR = 2.01, 95% CI 1.89–2.15) and macrosomia (RR = 1.40, 95% CI 1.21–1.62). Maternal obesity amplifies these risks, with a 3.22-fold increase for LGA (95% CI 2.17–4.79) and a 3.71-fold increase for macrosomia (95% CI 2.76–4.98), and a mean birth weight increase of 176 g [103]. The primary mechanism involves maternal hyperglycemia, which induces fetal hyperinsulinemia. Transplacental glucose transfer stimulates β-cell hyperplasia, enhancing lipogenesis and protein synthesis while inhibiting lipolysis, thereby accelerating fetal growth [104].
GDM-associated metabolic disturbances also exacerbate fetal nutrient overload. Tang et al. found a positive correlation between third-trimester maternal branched-chain amino acid (BCAA) levels and neonatal weight (r = 0.546, P = 0.035), suggesting that excessive placental BCAA transfer promotes fetal adipogenesis and myogenesis, contributing to macrosomia and LGA [105]. Notably, different subtypes of GDM impact fetal growth distinctively. A prospective cohort study contrasting the impaired fasting glucose (GDM-IFG) and impaired glucose tolerance (GDM-IGT) subtypes showed that GDM-IFG, marked by heightened insulin resistance, is linked to greater birth weight (3.43 kg vs. 3.32 kg, P < 0.05) and an elevated risk of LGA (RR = 1.76, 95% CI 1.26–2.45, P < 0.001). In contrast, GDM-IGT moderately elevates LGA risk (RR = 1.45, 95% CI 1.03–2.03, P = 0.032) but may also predispose to growth restriction via β-cell dysfunction, yielding attenuated effects compared to GDM-IFG [106].
Gestational thyroid disorders
Thyroid disorders during pregnancy, particularly thyroid autoimmunity (TAI), have gained significant attention due to their impact on ART outcomes. Evidence suggests that TAI-positive women not only face DOR and reduced oocyte yield but may also influence offspring birth weight through multifactorial mechanisms [107]. The transplacental transport of maternal thyroid hormones (T3/T4) during weeks 18 to 20 of pregnancy, when the fetal thyroid is immature, plays a crucial role in fetal growth [108]. Thyroid dysfunction exhibits bidirectional regulatory effects: clinical hypothyroidism (OR = 1.24; 95% CI 1.04–1.48) and Graves’ hyperthyroidism significantly increase the risk of SGA infants. In contrast, isolated hypothyroxinemia (decreased free thyroxine [FT4] with normal thyroid-stimulating hormone [TSH]) correlates with a 2.088-fold higher risk for LGA infants (95% CI 1.193–3.654) and a 45 g increase in birth weight [109]. This paradox may reflect trimester-dependent thyroid hormone metabolism, as each 1-SD increase in maternal FT4 during mid-to-late gestation is associated with a 21 g reduction in birth weight (P < 0.001), suggesting stage-specific thyroid-mediated growth regulation [109]. Immunologically, thyroid peroxidase antibody (TPOAb) positivity further amplifies SGA risk by disrupting placental hormone transport pathways (OR = 2.094; 95% CI 1.333–3.290) [110]. Collectively, these findings suggest that gestational thyroid dysregulation alters ART fetal growth trajectories through pathophysiological mechanisms, including impaired placental transport, compromised embryonic development, and uterine microenvironmental imbalances.
Genetic factors
Epigenetic alterations associated with ART
The core epigenetic mechanism by which ART influences offspring birth weight involves potential disruption of genomic imprinting establishment and epigenetic reprogramming during critical developmental windows, including gamete maturation, fertilization, and preimplantation embryo development. Acting as an environmental stressor, ART induces significant DNA methylation aberrations in the placenta and cord blood, particularly at major imprinting control regions (ICRs) (e.g., H19, KvDMR1, SNRPN). This is confirmed in both murine models and human studies [111, 112]. These epigenetic dysregulations (encompassing DNA methylation, histone modifications, and non-coding RNA alterations) cause an imbalance in the imprinted gene network. This typically manifests as downregulation of paternally expressed growth-promoting genes (e.g., IGF2, DLK1, PEG3) and upregulation of maternally expressed growth-restricting genes (e.g., H19, CDKN1C, PHLDA2) within the placenta [112, 113]. This genomic imprinting imbalance alters the placental transcriptome and impairs critical placental functions, such as vascularization and nutrient transport activity. This is evidenced by the downregulation of transporters like SLC7A5, SLC38A5, and ABCA1 [113], ultimately constraining fetal growth. The impact of ART protocols varies specifically and is linked to distinct epigenetic perturbations. Fresh-ET is often associated with an elevated risk of LBW/SGA, which may be linked to acute stress from ovarian stimulation and fresh transfer (e.g., suppressed PEG10 expression causing placental hypoplasia) [114]. In contrast, FET may reduce SGA risk but paradoxically increases LGA susceptibility. This likely reflects either hypercompensation for early epigenetic disturbances or FET-specific epigenetic alterations affecting metabolic programming [114].
Future studies should delineate how specific ART interventions (culture media composition, oxygen tension, cryoprotectants) drive multidimensional epigenetic changes (DNA methylation, ncRNA) to regulate key placental pathways. These include the HIF/miR-210-mediated hypoxia response, nutrient-sensing pathways, and the imprinted gene network. Integrating epigenomic and transcriptomic data via multi-omics strategies represents a cutting-edge approach to elucidate the mechanisms mediating ART’s effects on birth weight [113].
Fetal intrinsic genetic factors
Fetal genetic factors, independent of ART, significantly influence growth and development by determining growth potential and individual variability. Chromosomal aneuploidies (e.g., trisomy 21, 18, 13) and sex chromosome abnormalities (e.g., Turner syndrome) directly cause intrauterine growth restriction [115]. Chromosomal microdeletions/duplications (e.g., 15q26.3 IGF1R deletion or 2q11.1q11.2 duplication) disrupt critical growth signaling pathways, leading to developmental delays [116]. Monogenic mutations can have dual effects: BCS1L missense mutations impair mitochondrial respiratory chain function, causing severe growth restriction [117]. Recent evidence further implicates mitochondrial genome integrity in this process. Notably, an increased burden of de novo mtDNA variants, particularly nonsynonymous mutations and rRNA region alterations observed in ART-conceived children, has been linked to compromised mitochondrial function and bioenergetic insufficiency. This constitutes another intrinsic fetal pathway predisposing to restricted growth and LBW [118]. Fetal GCK mutations modulate insulin secretion, resulting in LBW or compensatory overgrowth, depending on maternal mutation status [119]. Genomic imprinting disorders (e.g., 11p15 H19/IGF2 or CDKN1C/KCNQ1OT1 dysregulation) drive Silver-Russell syndrome (growth restriction) and Beckwith-Wiedemann syndrome (overgrowth) [120]. Metabolic gene polymorphisms (e.g., MTHFR, CYP2E1, GSTM1) increase the risk of LBW by impairing folate metabolism or oxidative stress defense [121]. These genetic variations, through placental dysfunction or fetal metabolic programming disturbances, interact with ART-associated epigenetic modifications to shape birth weight outcomes.
Other factors
Our comprehensive analysis indicates that birth weight in ART-conceived offspring is influenced by multifaceted factors, encompassing maternal, ART procedural, and genetic aspects, with maternal infertility etiology and ART-specific factors (summarized in Tables 1 and 2) representing critical factors unique to this population.
Notably, beyond these core elements, confounders including parental age, ethnicity, maternal BMI, gestational nutrition, prenatal tobacco exposure, fetal sex, and environmental factors exert conception-independent effects on birth weight [122–127]; for instance, advanced parental age independently increases PTB, FGR, and LBW risks (with ART populations being generally older); high maternal BMI correlates positively with LGA, while low BMI elevates PTB/SGA susceptibility [124]; males typically exhibit higher birth weights than females [126]; and ethnic disparities are well established [123]. Within ART cohorts, these factors may interact with ART procedural variables to amplify or mitigate specific risks. Disentangling these interconnected influences remains challenging, necessitating future multivariate models integrating ART-specific variables, maternal comorbidities, and fetal characteristics. Prospective cohorts should further incorporate environmental epigenetic biomarkers (e.g., cord blood DNA methylation signature) and placental functional markers (e.g., serial Doppler indices, placental mRNA expression profiling) to elucidate how confounders independently or synergistically affect offspring growth via the maternal-placental-fetal axis.
The long-term growth of ART offspring
As can be seen from the various factors discussed earlier, the combined effect of most ART-related factors and their interaction with confounders increases the risk of LBW and SGA in offspring conceived through ART, leading to their smaller body size. Birth weight can reflect the intrauterine programming effect, and this effect may continuously influence the postnatal growth trajectory. We have compiled the relevant literatures in recent years regarding the postnatal growth trajectories of offspring conceived through ART, as shown in Appendix Table 3. Initial birth weight discrepancies drive compensatory growth postnatally, particularly during the 0–3-year period, marked by accelerated weight gain (+ 0.12 kg/year, P < 0.05) [128]. While anthropometric parameters in most ART offspring converge with those of naturally conceived peers by school age or adolescence, critical divergences remain (Appendix Table 3). For instance, fresh-ET newborns exhibit reduced birth weight, length, and head circumference [9, 129], whereas FET offspring display birth weights comparable to or exceeding naturally conceived levels. This disparity may result from FET’s ability to optimize embryo-endometrial synchrony, enhancing early growth stability. However, FET offspring demonstrate a trend toward elevated BMI at 12–24 months (P = 0.06) [130] and a 32% increased risk of adolescent obesity [131], underscoring that birth weight normalization does not equate to metabolic health restoration.
Globally, growth patterns in ART offspring lack uniformity (Appendix Table 3). For example, in the Norwegian MoBa cohort, ART offspring exhibited sustained larger body sizes than naturally conceived peers up to 3 years after catch-up growth [128]. Conversely, meta-analyses integrating 26 multicenter cohorts found smaller body sizes in ART children compared to naturally conceived groups during infancy and childhood, with differences resolving only by adolescence [132]. Such contradictions likely arise from interactions between ART protocol heterogeneity and population-specific factors. Sex-specific growth dynamics further complicate this picture: FET-conceived males show prolonged weight catch-up until age 6, while female catch-up plateaus by age 3, potentially reflecting greater compensatory nutritional demands in males [133]. These findings collectively emphasize that clinical interpretation of birth weight, a core safety indicator in ART, must account for both causal factors and long-term metabolic trajectories.
Existing evidence on ART offspring growth has notable limitations. Most longitudinal studies lack granular ART technical details (e.g., embryo transfer protocols), hindering mechanistic exploration of growth variances. Furthermore, follow-up typically concludes at adolescence, precluding evaluation of adulthood chronic disease risks. Animal-derived insights into placental compensatory mechanisms (e.g., vascular remodeling, nutrient transport) remain insufficiently validated in human cohorts. Critically, interpreting associations between ART and offspring health outcomes, including growth trajectories, necessitates careful distinction between correlation and causation. Parental background characteristics and the underlying infertility etiology itself represent significant confounding factors in current observational studies. Future research should establish interdisciplinary platforms integrating multi-omics data and refined ART classification systems to model causal pathways from birth weight to lifelong health outcomes and prioritize studies specifically designed to elucidate the causal mechanisms by which ART technologies per se, key procedural steps, and concomitant maternal environmental changes impact embryo-maternal crosstalk and placental development, enabling personalized embryo transfer strategies only after such causal chains are established.
References
- 1.Smeenk J, Wyns C, De Geyter C, Kupka M, Bergh C, Cuevas Saiz I, et al. ART in Europe, 2019: results generated from European registries by ESHRE. Hum Reprod. 2023;38(12):2321–38. 10.1093/humrep/dead197. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Zhang S, Luo Q, Meng R, Yan J, Wu Y, Huang H. Long-term health risk of offspring born from assisted reproductive technologies. J Assist Reprod Genet. 2024;41(3):527–50. 10.1007/s10815-023-02988-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Barker DJ. The origins of the developmental origins theory. J Intern Med. 2007;261(5):412–7. 10.1111/j.1365-2796.2007.01809.x. [DOI] [PubMed] [Google Scholar]
- 4.Berntsen S, Söderström-Anttila V, Wennerholm UB, Laivuori H, Loft A, Oldereid NB, et al. The health of children conceived by ART: ‘the chicken or the egg?’ Hum Reprod Update. 2019;25(2):137–58. 10.1093/humupd/dmz001. [DOI] [PubMed] [Google Scholar]
- 5.Bloise E, Feuer SK, Rinaudo PF. Comparative intrauterine development and placental function of ART concepti: implications for human reproductive medicine and animal breeding. Hum Reprod Update. 2014;20(6):822–39. 10.1093/humupd/dmu032. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.van Duijn L, Hoek J, Rousian M, Baart EB, Willemsen SP, Laven JSE, et al. Prenatal growth trajectories and birth outcomes after frozen-thawed extended culture embryo transfer and fresh embryo transfer: the Rotterdam periconception cohort. Reprod Biomed Online. 2021;43(2):279–87. 10.1016/j.rbmo.2021.04.013. [DOI] [PubMed] [Google Scholar]
- 7.Cavoretto PI, Farina A, Girardelli S, Gaeta G, Spinillo S, Morano D, et al. Greater fetal crown-rump length growth with the use of in vitro fertilization or intracytoplasmic sperm injection conceptions after thawed versus fresh blastocyst transfers: secondary analysis of a prospective cohort study. Fertil Steril. 2021;116(1):147–56. 10.1016/j.fertnstert.2020.11.035. [DOI] [PubMed] [Google Scholar]
- 8.Cavoretto PI, Farina A, Gaeta G, Seidenari A, Pozzoni M, Spinillo S, et al. Greater estimated fetal weight and birth weight in IVF/ICSI pregnancy after frozen-thawed vs fresh blastocyst transfer: prospective cohort study with novel unified modeling methodology. Ultrasound Obstet Gynecol. 2022;60(1):76–85. 10.1002/uog.24806. [DOI] [PubMed] [Google Scholar]
- 9.Turner S, Maclean E, Dick S, Aucott L, Maheshwari A. Is conception by in vitro fertilization associated with altered antenatal and postnatal growth trajectories? Fertil Steril. 2020;114(6):1216–24. 10.1016/j.fertnstert.2020.06.039. [DOI] [PubMed] [Google Scholar]
- 10.Cavoretto PI, Farina A, Gaeta G, Sigismondi C, Spinillo S, Casiero D, et al. Uterine artery Doppler in singleton pregnancies conceived after in-vitro fertilization or intracytoplasmic sperm injection with fresh vs frozen blastocyst transfer: longitudinal cohort study. Ultrasound Obstet Gynecol. 2020;56(4):603–10. 10.1002/uog.21969. [DOI] [PubMed] [Google Scholar]
- 11.Li X, Jauniaux E, Antenatal fetal growth patterns in uncomplicated pregnancies according to mode of conception and placental location. Placenta. 2024;145(89–91. 10.1016/j.placenta.2023.11.016 [DOI] [PubMed]
- 12.Terho AM, Pelkonen S, Opdahl S, Romundstad LB, Bergh C, Wennerholm UB, et al. High birth weight and large-for-gestational-age in singletons born after frozen compared to fresh embryo transfer, by gestational week: a Nordic register study from the CoNARTaS group. Hum Reprod. 2021;36(4):1083–92. 10.1093/humrep/deaa304. [DOI] [PubMed] [Google Scholar]
- 13.Magnusson Å, Laivuori H, Loft A, Oldereid NB, Pinborg A, Petzold M, et al., The association between high birth weight and long-term outcomes-implications for assisted reproductive technologies: a systematic review and meta-analysis. Front Pediatr. 2021;9(675775. 10.3389/fped.2021.675775 [DOI] [PMC free article] [PubMed]
- 14.Ong KK, Dunger DB. Perinatal growth failure: the road to obesity, insulin resistance and cardiovascular disease in adults. Best Pract Res Clin Endocrinol Metab. 2002;16(2):191–207. 10.1053/beem.2002.0195. [DOI] [PubMed] [Google Scholar]
- 15.Ong KK, Ahmed ML, Emmett PM, Preece MA, Dunger DB. Association between postnatal catch-up growth and obesity in childhood: prospective cohort study. BMJ. 2000;320(7240):967–71. 10.1136/bmj.320.7240.967. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Bahri Khomami M, Hashemi S, Shorakae S, Harrison CL, Piltonen TT, Romualdi D, et al. Systematic review and meta-analysis of birth outcomes in women with polycystic ovary syndrome. Nat Commun. 2024;15(1):5592. 10.1038/s41467-024-49752-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Talmo MSA, Fløysand IS, Nilsen G, Løvvik TS, Ødegård R, Juliusson PB, et al. Growth restriction in the offspring of mothers with polycystic ovary syndrome. JAMA Netw Open. 2024;7(8): e2430543. 10.1001/jamanetworkopen.2024.30543. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Abbott DH, Dumesic DA, Eisner JR, Colman RJ, Kemnitz JW. Insights into the development of polycystic ovary syndrome (PCOS) from studies of prenatally androgenized female rhesus monkeys. Trends Endocrinol Metab. 1998;9(2):62–7. 10.1016/s1043-2760(98)00019-8. [DOI] [PubMed] [Google Scholar]
- 19.Sun M, Maliqueo M, Benrick A, Johansson J, Shao R, Hou L, et al. Maternal androgen excess reduces placental and fetal weights, increases placental steroidogenesis, and leads to long-term health effects in their female offspring. Am J Physiol Endocrinol Metab. 2012;303(11):E1373–85. 10.1152/ajpendo.00421.2012. [DOI] [PubMed] [Google Scholar]
- 20.Sathishkumar K, Elkins R, Chinnathambi V, Gao H, Hankins GD, Yallampalli C, Prenatal testosterone-induced fetal growth restriction is associated with down-regulation of rat placental amino acid transport. Reprod Biol Endocrinol. 2011;9(110. 10.1186/1477-7827-9-110 [DOI] [PMC free article] [PubMed]
- 21.Palomba S, Falbo A, Chiossi G, Orio F, Tolino A, Colao A, et al. Low-grade chronic inflammation in pregnant women with polycystic ovary syndrome: a prospective controlled clinical study. J Clin Endocrinol Metab. 2014;99(8):2942–51. 10.1210/jc.2014-1214. [DOI] [PubMed] [Google Scholar]
- 22.Kawwass JF, Crawford S, Kissin DM, Session DR, Boulet S, Jamieson DJ. Tubal factor infertility and perinatal risk after assisted reproductive technology. Obstet Gynecol. 2013;121(6):1263–71. 10.1097/AOG.0b013e31829006d9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Sunkara SK, Antonisamy B, Redla AC, Kamath MS. Female causes of infertility are associated with higher risk of preterm birth and low birth weight: analysis of 117 401 singleton live births following IVF. Hum Reprod. 2021;36(3):676–82. 10.1093/humrep/deaa283. [DOI] [PubMed] [Google Scholar]
- 24.Huang CC, Huang CC, Lin SY, Chang CY, Lin WC, Chung CH, et al. Association of pelvic inflammatory disease (PID) with ectopic pregnancy and preterm labor in Taiwan: a nationwide population-based retrospective cohort study. PLoS ONE. 2019;14(8): e0219351. 10.1371/journal.pone.0219351. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Stephens AJ, Aubuchon M, Schust DJ, Antichlamydial antibodies, human fertility, and pregnancy wastage. Infect Dis Obstet Gynecol. 2011;2011(525182. 10.1155/2011/525182 [DOI] [PMC free article] [PubMed]
- 26.Farland LV, Prescott J, Sasamoto N, Tobias DK, Gaskins AJ, Stuart JJ, et al. Endometriosis and risk of adverse pregnancy outcomes. Obstet Gynecol. 2019;134(3):527–36. 10.1097/aog.0000000000003410. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Lalani S, Choudhry AJ, Firth B, Bacal V, Walker M, Wen SW, et al. Endometriosis and adverse maternal, fetal and neonatal outcomes, a systematic review and meta-analysis. Hum Reprod. 2018;33(10):1854–65. 10.1093/humrep/dey269. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Ibiebele I, Nippita T, Baber R, Torvaldsen S. Pregnancy outcomes in women with endometriosis and/or ART use: a population-based cohort study. Hum Reprod. 2022;37(10):2350–8. 10.1093/humrep/deac186. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Vercellini P, Viganò P, Bandini V, Buggio L, Berlanda N, Somigliana E. Association of endometriosis and adenomyosis with pregnancy and infertility. Fertil Steril. 2023;119(5):727–40. 10.1016/j.fertnstert.2023.03.018. [DOI] [PubMed] [Google Scholar]
- 30.Nirgianakis K, Kalaitzopoulos DR, Schwartz ASK, Spaanderman M, Kramer BW, Mueller MD, et al. Fertility, pregnancy and neonatal outcomes of patients with adenomyosis: a systematic review and meta-analysis. Reprod Biomed Online. 2021;42(1):185–206. 10.1016/j.rbmo.2020.09.023. [DOI] [PubMed] [Google Scholar]
- 31.Shin YJ, Kwak DW, Chung JH, Kim MY, Lee SW, Han YJ. The risk of preterm births among pregnant women with adenomyosis. J Ultrasound Med. 2018;37(8):1937–43. 10.1002/jum.14540. [DOI] [PubMed] [Google Scholar]
- 32.Rees CO, van Vliet H, Siebers A, Bulten J, Huppelschoten A, Westerhuis M, et al. The ADENO study: adenomyosis and its effect on neonatal and obstetric outcomes: a retrospective population-based study. Am J Obstet Gynecol. 2023;229(1):49.e1-49.e12. 10.1016/j.ajog.2022.12.013. [DOI] [PubMed] [Google Scholar]
- 33.Khan KN, Fujishita A, Mori T. Pathogenesis of human adenomyosis: current understanding and its association with infertility. J Clin Med. 2022. 10.3390/jcm11144057. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Salmeri N, Farina A, Candiani M, Dolci C, Bonavina G, Poziello C, et al., Endometriosis and impaired placentation: a prospective cohort study comparing uterine arteries Doppler pulsatility index in pregnancies of patients with and without moderate-severe disease. Diagnostics (Basel). 2022;12(5). 10.3390/diagnostics12051024 [DOI] [PMC free article] [PubMed]
- 35.Zhao M, Wang D, Zhang Y, Wang L. Evaluating pregnancy outcomes in women with uterine fibroids treated with high-intensity focused ultrasound: insights from a single-institution study. Reprod Health. 2024;21(1):184. 10.1186/s12978-024-01930-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Harlev A, Wainstock T, Walfisch A, Landau D, Sheiner E, Perinatal outcome and long-term pediatric morbidity of pregnancies with a fibroid uterus. Early Hum Dev. 2019;129(33–37. 10.1016/j.earlhumdev.2019.01.004 [DOI] [PubMed]
- 37.Egbe TO, Badjang TG, Tchounzou R, Egbe EN, Ngowe MN. Uterine fibroids in pregnancy: prevalence, clinical presentation, associated factors and outcomes at the Limbe and Buea Regional Hospitals, Cameroon: a cross-sectional study. BMC Res Notes. 2018;11(1):889. 10.1186/s13104-018-4007-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Li H, Hu Z, Fan Y, Hao Y. The influence of uterine fibroids on adverse outcomes in pregnant women: a meta-analysis. BMC Pregnancy Childbirth. 2024;24(1):345. 10.1186/s12884-024-06545-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Wang X, Wang G, Han R, Gao M, Wang F, Hong Y, et al., Uterine fibroids increase the risk of preterm birth and other adverse birth events: a systematic review and meta-analysis. Transl Pediatr. 2022;11(6):978–986. 10.21037/tp-22-215 [DOI] [PMC free article] [PubMed]
- 40.Bucuri C, Mihu D, Malutan A, Oprea V, Berceanu C, Nati I, et al., Fetal ovarian cyst-a scoping review of the data from the last 10 years. Medicina (Kaunas). 2023;59(2). 10.3390/medicina59020186 [DOI] [PMC free article] [PubMed]
- 41.Melinte-Popescu AS, Popa RF, Harabor V, Nechita A, Harabor A, Adam AM, et al., Managing fetal ovarian cysts: clinical experience with a rare disorder. Medicina (Kaunas). 2023;59(4). 10.3390/medicina59040715 [DOI] [PMC free article] [PubMed]
- 42.Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006;12(6):685–718. 10.1093/humupd/dml034. [DOI] [PubMed] [Google Scholar]
- 43.Abdullah RK, Liu N, Zhao Y, Shuang Y, Shen Z, Zeng H, et al. Cumulative live-birth, perinatal and obstetric outcomes for POSEIDON groups after IVF/ICSI cycles: a single-center retrospective study. Sci Rep. 2020;10(1):11822. 10.1038/s41598-020-68896-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Hu S, Xu B, Jin L. Perinatal outcome in young patients with diminished ovarian reserve undergoing assisted reproductive technology. Fertil Steril. 2020;114(1):118-124.e1. 10.1016/j.fertnstert.2020.02.112. [DOI] [PubMed] [Google Scholar]
- 45.Can S, Yang X, He Y, Wang C, Zou H, Fan Q, et al. Diminished ovarian reserve associates with pregnancy and birth outcomes after IVF: a retrospective cohort study. Hum Fertil (Camb). 2024;27(1):2414813. 10.1080/14647273.2024.2414813. [DOI] [PubMed] [Google Scholar]
- 46.Ma S, Liao J, Zhang S, Yang X, Hocher B, Tan J, et al. Exploring the efficacy and beneficial population of preimplantation genetic testing for aneuploidy start from the oocyte retrieval cycle: a real-world study. J Transl Med. 2023;21(1):779. 10.1186/s12967-023-04641-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Calhoun KC, Fritz MA, Steiner AZ. Examining the relationship between ovarian reserve, as measured by basal FSH levels, and the risk of poor obstetric outcome in singleton IVF gestations. Hum Reprod. 2011;26(12):3424–30. 10.1093/humrep/der311. [DOI] [PubMed] [Google Scholar]
- 48.De Vos ES, Mulders A, Koning AHJ, Willemsen SP, Rousian M, Van Rijn BB, et al. Morphologic development of the first-trimester utero-placental vasculature is positively associated with embryonic and fetal growth: the Rotterdam periconception cohort. Hum Reprod. 2024;39(5):923–35. 10.1093/humrep/deae056. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Gyselaers W. Origins of abnormal placentation: why maternal veins must not be forgotten. Am J Obstet Gynecol. 2023;228(6):613–21. 10.1016/j.ajog.2022.12.014. [DOI] [PubMed] [Google Scholar]
- 50.Liu Y, Li J, Zhang W, Guo Y. Association between serum oestradiol level on the hCG administration day and neonatal birthweight after IVF-ET among 3659 singleton live births. Sci Rep. 2021;11(1):6084. 10.1038/s41598-021-85692-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Zhang W, Ma Y, Xiong Y, Xiao X, Chen S, Wang X. Supraphysiological serum oestradiol negatively affects birthweight in cryopreserved embryo transfers: a retrospective cohort study. Reprod Biomed Online. 2019;39(2):312–20. 10.1016/j.rbmo.2019.04.015. [DOI] [PubMed] [Google Scholar]
- 52.Cai J, Liu L, Xu Y, Liu Z, Jiang X, Li P, et al. Supraphysiological estradiol level in ovarian stimulation cycles affects the birthweight of neonates conceived through subsequent frozen-thawed cycles: a retrospective study. BJOG. 2019;126(6):711–8. 10.1111/1471-0528.15606. [DOI] [PubMed] [Google Scholar]
- 53.Hu XL, Feng C, Lin XH, Zhong ZX, Zhu YM, Lv PP, et al. High maternal serum estradiol environment in the first trimester is associated with the increased risk of small-for-gestational-age birth. J Clin Endocrinol Metab. 2014;99(6):2217–24. 10.1210/jc.2013-3362. [DOI] [PubMed] [Google Scholar]
- 54.Qu Y, Zhang J, Guo S, Zhang L, Qian J, Zhu X, et al., Three-dimensional visualization of mouse endometrial remodeling after superovulation. Front Cell Dev Biol. 2022;10(933852. 10.3389/fcell.2022.933852 [DOI] [PMC free article] [PubMed]
- 55.Maheshwari A, Pandey S, Amalraj Raja E, Shetty A, Hamilton M, Bhattacharya S. Is frozen embryo transfer better for mothers and babies? Can cumulative meta-analysis provide a definitive answer? Hum Reprod Update. 2018;24(1):35–58. 10.1093/humupd/dmx031. [DOI] [PubMed] [Google Scholar]
- 56.Luke B, Brown MB, Wantman E, Stern JE, Toner JP, Coddington CC 3rd. Increased risk of large-for-gestational age birthweight in singleton siblings conceived with in vitro fertilization in frozen versus fresh cycles. J Assist Reprod Genet. 2017;34(2):191–200. 10.1007/s10815-016-0850-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Shavit M, Miller N, Schreiber H, Asali A, Ravid D, Harlev A, et al. Twin pregnancies and perinatal outcomes: a comparison between fresh and frozen embryo transfer: a two-centre study. Reprod Biomed Online. 2019;38(2):241–8. 10.1016/j.rbmo.2018.11.004. [DOI] [PubMed] [Google Scholar]
- 58.Westvik-Johari K, Romundstad LB, Lawlor DA, Bergh C, Gissler M, Henningsen AA, et al. Separating parental and treatment contributions to perinatal health after fresh and frozen embryo transfer in assisted reproduction: a cohort study with within-sibship analysis. PLoS Med. 2021;18(6): e1003683. 10.1371/journal.pmed.1003683. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Amor DJ, Xu JX, Halliday JL, Francis I, Healy DL, Breheny S, et al. Pregnancies conceived using assisted reproductive technologies (ART) have low levels of pregnancy-associated plasma protein-A (PAPP-A) leading to a high rate of false-positive results in first trimester screening for Down syndrome. Hum Reprod. 2009;24(6):1330–8. 10.1093/humrep/dep046. [DOI] [PubMed] [Google Scholar]
- 60.Kansal Kalra S, Ratcliffe SJ, Milman L, Gracia CR, Coutifaris C, Barnhart KT. Perinatal morbidity after in vitro fertilization is lower with frozen embryo transfer. Fertil Steril. 2011;95(2):548–53. 10.1016/j.fertnstert.2010.05.049. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.van Duijn L, Rousian M, Reijnders IF, Willemsen SP, Baart EB, Laven JSE, et al. The influence of frozen-thawed and fresh embryo transfer on utero-placental (vascular) development: the Rotterdam periconception cohort. Hum Reprod. 2021;36(8):2091–100. 10.1093/humrep/deab070. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Pinborg A, Henningsen AK, Malchau SS, Loft A. Congenital anomalies after assisted reproductive technology. Fertil Steril. 2013;99(2):327–32. 10.1016/j.fertnstert.2012.12.001. [DOI] [PubMed] [Google Scholar]
- 63.Ginström Ernstad E, Wennerholm UB, Khatibi A, Petzold M, Bergh C. Neonatal and maternal outcome after frozen embryo transfer: increased risks in programmed cycles. Am J Obstet Gynecol. 2019;221(2):126.e1-126.e18. 10.1016/j.ajog.2019.03.010. [DOI] [PubMed] [Google Scholar]
- 64.Hesters L, Sermondade N, Lambert C, Pouly JL, Pereira B, Lucas C, et al. Is large for gestational age in singletons born after frozen embryo transfer associated with freezing technique or endometrial preparation protocol? A longitudinal national French study, Hum Reprod. 2024;39(4):724–32. 10.1093/humrep/deae027. [DOI] [PubMed] [Google Scholar]
- 65.Wang B, Zhang J, Zhu Q, Yang X, Wang Y. Effects of different cycle regimens for frozen embryo transfer on perinatal outcomes of singletons. Hum Reprod. 2020;35(7):1612–22. 10.1093/humrep/deaa093. [DOI] [PubMed] [Google Scholar]
- 66.Zong L, Liu P, Zhou L, Wei D, Ding L, Qin Y. Increased risk of maternal and neonatal complications in hormone replacement therapy cycles in frozen embryo transfer. Reprod Biol Endocrinol. 2020;18(1):36. 10.1186/s12958-020-00601-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Hu KL, Zhang D, Li R. Endometrium preparation and perinatal outcomes in women undergoing single-blastocyst transfer in frozen cycles. Fertil Steril. 2021;115(6):1487–94. 10.1016/j.fertnstert.2020.12.016. [DOI] [PubMed] [Google Scholar]
- 68.Lee JC, Badell ML, Kawwass JF. The impact of endometrial preparation for frozen embryo transfer on maternal and neonatal outcomes: a review. Reprod Biol Endocrinol. 2022;20(1):40. 10.1186/s12958-021-00869-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Hu KL, Kawai A, Hunt S, Li W, Li X, Zhang R, et al. Endometrial thickness in the prediction of neonatal adverse outcomes in frozen cycles for singleton pregnancies. Reprod Biomed Online. 2021;43(3):553–60. 10.1016/j.rbmo.2021.04.014. [DOI] [PubMed] [Google Scholar]
- 70.Wu J, Huang J, Dong J, Xiao X, Li M, Wang X, The thicker the endometrium, the better the neonatal outcomes?, Hum Reprod Open. 2023;2023(3):hoad028. 10.1093/hropen/hoad028 [DOI] [PMC free article] [PubMed]
- 71.He T, Li M, Li W, Meng P, Xue X, Shi J, Endometrial thickness is associated with low birthweight in frozen embryo transfer cycles: a retrospective cohort study of 8,235 singleton newborns, Front Endocrinol (Lausanne). 2022;13(929617. 10.3389/fendo.2022.929617 [DOI] [PMC free article] [PubMed]
- 72.Guo Z, Xu X, Zhang L, Zhang L, Yan L, Ma J. Endometrial thickness is associated with incidence of small-for-gestational-age infants in fresh in vitro fertilization-intracytoplasmic sperm injection and embryo transfer cycles. Fertil Steril. 2020;113(4):745–52. 10.1016/j.fertnstert.2019.12.014. [DOI] [PubMed] [Google Scholar]
- 73.Zhang J, Liu H, Mao X, Chen Q, Si J, Fan Y, et al. Effect of endometrial thickness on birthweight in frozen embryo transfer cycles: an analysis including 6181 singleton newborns. Hum Reprod. 2019;34(9):1707–15. 10.1093/humrep/dez103. [DOI] [PubMed] [Google Scholar]
- 74.Fang Z, Huang J, Mao J, Yu L, Wang X. Effect of endometrial thickness on obstetric and neonatal outcomes in assisted reproduction: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2023;21(1):55. 10.1186/s12958-023-01105-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Raja EA, Bhattacharya S, Maheshwari A, McLernon DJ, A comparison of perinatal outcomes following fresh blastocyst or cleavage stage embryo transfer in singletons and twins and between singleton siblings, Hum Reprod Open. 2023;2023(2):hoad003. 10.1093/hropen/hoad003 [DOI] [PMC free article] [PubMed]
- 76.Marconi N, Allen CP, Bhattacharya S, Maheshwari A. Obstetric and perinatal outcomes of singleton pregnancies after blastocyst-stage embryo transfer compared with those after cleavage-stage embryo transfer: a systematic review and cumulative meta-analysis. Hum Reprod Update. 2022;28(2):255–81. 10.1093/humupd/dmab042. [DOI] [PubMed] [Google Scholar]
- 77.Ma X, Wang J, Shi Y, Tan J, Guan Y, Sun Y, et al. Effect of single blastocyst-stage versus single cleavage-stage embryo transfer on cumulative live births in women with good prognosis undergoing in vitro fertilization: multicenter randomized controlled trial. Nat Commun. 2024;15(1):7747. 10.1038/s41467-024-52008-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Pier BD, Roshong A, Santoro N, Sammel MD. Association of duration of embryo culture with risk of large for gestational age delivery in cryopreserved embryo transfer cycles. Fertil Steril. 2024;121(5):814–23. 10.1016/j.fertnstert.2024.01.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Oberg AS, VanderWeele TJ, Almqvist C, Hernandez-Diaz S. Pregnancy complications following fertility treatment-disentangling the role of multiple gestation. Int J Epidemiol. 2018;47(4):1333–42. 10.1093/ije/dyy103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.Ma S, Peng Y, Hu L, Wang X, Xiong Y, Tang Y, et al. Comparisons of benefits and risks of single embryo transfer versus double embryo transfer: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2022;20(1):20. 10.1186/s12958-022-00899-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81.Rodriguez-Wallberg KA, Palomares AR, Nilsson HP, Oberg AS, Lundberg F. Obstetric and perinatal outcomes of singleton births following single- vs double-embryo transfer in Sweden. JAMA Pediatr. 2023;177(2):149–59. 10.1001/jamapediatrics.2022.4787. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Kamath MS, Antonisamy B, Selliah HY, Sunkara SK. Perinatal outcomes of singleton live births with and without vanishing twin following transfer of multiple embryos: analysis of 113 784 singleton live births. Hum Reprod. 2018;33(11):2018–22. 10.1093/humrep/dey284. [DOI] [PubMed] [Google Scholar]
- 83.Li J, Li J, Zhang Y, Hu K, Chen N, Gao J, et al., The influence of the vanishing twin on the perinatal outcome of surviving singleton in IVF pregnancy, Front Endocrinol (Lausanne). 2022;13(832665. 10.3389/fendo.2022.832665 [DOI] [PMC free article] [PubMed]
- 84.Zhang J, Huang J, Liu H, Wang B, Yang X, Shen X, et al. The impact of embryo quality on singleton birthweight in vitrified-thawed single blastocyst transfer cycles. Hum Reprod. 2020;35(2):308–16. 10.1093/humrep/dez287. [DOI] [PubMed] [Google Scholar]
- 85.Shi S, Zhao B, Hu Z, Shi Q. The impact of blastocyst grade on singleton birth weight in fresh IVF-ET cycles in ART: a retrospective study. BMC Pregnancy Childbirth. 2024;24(1):588. 10.1186/s12884-024-06794-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86.Huang J, Tao Y, Zhang J, Yang X, Wu J, Kuang Y, et al., Poor embryo quality is associated with a higher risk of low birthweight in vitrified-warmed single embryo transfer cycles, Front Physiol. 2020;11(415. 10.3389/fphys.2020.00415 [DOI] [PMC free article] [PubMed]
- 87.He H, Jing S, Lu CF, Tan YQ, Luo KL, Zhang SP, et al. Neonatal outcomes of live births after blastocyst biopsy in preimplantation genetic testing cycles: a follow-up of 1,721 children. Fertil Steril. 2019;112(1):82–8. 10.1016/j.fertnstert.2019.03.006. [DOI] [PubMed] [Google Scholar]
- 88.Hou W, Shi G, Ma Y, Liu Y, Lu M, Fan X, et al. Impact of preimplantation genetic testing on obstetric and neonatal outcomes: a systematic review and meta-analysis. Fertil Steril. 2021;116(4):990–1000. 10.1016/j.fertnstert.2021.06.040. [DOI] [PubMed] [Google Scholar]
- 89.Zheng W, Yang C, Yang S, Sun S, Mu M, Rao M, et al. Obstetric and neonatal outcomes of pregnancies resulting from preimplantation genetic testing: a systematic review and meta-analysis. Hum Reprod Update. 2021;27(6):989–1012. 10.1093/humupd/dmab027. [DOI] [PubMed] [Google Scholar]
- 90.Alteri A, Cermisoni GC, Pozzoni M, Gaeta G, Cavoretto PI, Viganò P. Obstetric, neonatal, and child health outcomes following embryo biopsy for preimplantation genetic testing. Hum Reprod Update. 2023;29(3):291–306. 10.1093/humupd/dmad001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 91.Zhu J, Li M, Chen L, Liu P, Qiao J. The protein source in embryo culture media influences birthweight: a comparative study between G1 v5 and G1-PLUS v5. Hum Reprod. 2014;29(7):1387–92. 10.1093/humrep/deu103. [DOI] [PubMed] [Google Scholar]
- 92.Zandstra H, Brentjens L, Spauwen B, Touwslager RNH, Bons JAP, Mulder AL, et al. Association of culture medium with growth, weight and cardiovascular development of IVF children at the age of 9 years. Hum Reprod. 2018;33(9):1645–56. 10.1093/humrep/dey246. [DOI] [PubMed] [Google Scholar]
- 93.Kleijkers SH, Mantikou E, Slappendel E, Consten D, van Echten-Arends J, Wetzels AM, et al. Influence of embryo culture medium (G5 and HTF) on pregnancy and perinatal outcome after IVF: a multicenter RCT. Hum Reprod. 2016;31(10):2219–30. 10.1093/humrep/dew156. [DOI] [PubMed] [Google Scholar]
- 94.Kleijkers SH, van Montfoort AP, Smits LJ, Coonen E, Derhaag JG, Evers JL, et al. Age of G-1 PLUS v5 embryo culture medium is inversely associated with birthweight of the newborn. Hum Reprod. 2015;30(6):1352–7. 10.1093/humrep/dev075. [DOI] [PubMed] [Google Scholar]
- 95.Sacha CR, Gopal D, Liu CL, Cabral HR, Stern JE, Carusi DA, et al. The impact of single-step and sequential embryo culture systems on obstetric and perinatal outcomes in singleton pregnancies: the Massachusetts Outcomes Study of Assisted Reproductive Technology. Fertil Steril. 2022;117(6):1246–54. 10.1016/j.fertnstert.2022.03.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 96.Mann MR, Lee SS, Doherty AS, Verona RI, Nolen LD, Schultz RM, et al. Selective loss of imprinting in the placenta following preimplantation development in culture. Development. 2004;131(15):3727–35. 10.1242/dev.01241. [DOI] [PubMed] [Google Scholar]
- 97. Zhu H, Xu J, Cai J, Liu H, Zhao Z, Chen T, et al., Cohort profile: the Ningbo birth cohort of population undergoing assisted reproductive technology (NBart), Int J Epidemiol. 2024;53(4). 10.1093/ije/dyae086 [DOI] [PubMed]
- 98.Awuah SP, Okai I, Ntim EA, Bedu-Addo K. Prevalence, placenta development, and perinatal outcomes of women with hypertensive disorders of pregnancy at Komfo Anokye Teaching Hospital. PLoS ONE. 2020;15(10): e0233817. 10.1371/journal.pone.0233817. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 99.Chen Y, Wang Y, Li Y, Ding G, Zhang Y, Association of the severity of hypertensive disorders in pregnancy with birthweight, childhood obesity, and blood pressure at age 7, Nutrients. 2023;15(14). 10.3390/nu15143104 [DOI] [PMC free article] [PubMed]
- 100.Petersen SH, Åsvold BO, Lawlor DA, Pinborg A, Spangmose AL, Romundstad LB, et al. Preterm birth in assisted reproduction: the mediating role of hypertensive disorders in pregnancy. Hum Reprod. 2025;40(1):167–77. 10.1093/humrep/deae261. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 101.Tellechea M, Gianotti TF, Alvariñas J, González CD, Sookoian S, Pirola CJ, Telomere length in the two extremes of abnormal fetal growth and the programming effect of maternal arterial hypertension. Sci Rep. 2015;5(7869. 10.1038/srep07869 [DOI] [PMC free article] [PubMed]
- 102.Bosdou JK, Anagnostis P, Goulis DG, Lainas GT, Tarlatzis BC, Grimbizis GF, et al. Risk of gestational diabetes mellitus in women achieving singleton pregnancy spontaneously or after ART: a systematic review and meta-analysis. Hum Reprod Update. 2020;26(4):514–44. 10.1093/humupd/dmaa011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 103.Weir TL, Majumder M, Glastras SJ. A systematic review of the effects of maternal obesity on neonatal outcomes in women with gestational diabetes. Obes Rev. 2024;25(7): e13747. 10.1111/obr.13747. [DOI] [PubMed] [Google Scholar]
- 104.Sweeting A, Wong J, Murphy HR, Ross GP. A clinical update on gestational diabetes mellitus. Endocr Rev. 2022;43(5):763–93. 10.1210/endrev/bnac003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 105.Tang N, Liu Y, Yang S, Zhong M, Cui D, Chai O, et al. Correlation between newborn weight and serum BCAAs in pregnant women with diabetes. Nutr Diabetes. 2024;14(1):38. 10.1038/s41387-024-00301-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 106.Gong Y, Wang Q, Chen S, Liu Y, Li C, Kang R, et al. Heterogeneity of gestational diabetes and risk for adverse pregnancy outcome: a cohort study. J Clin Endocrinol Metab. 2024. 10.1210/clinem/dgae754. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 107.Huang N, Chen L, Lian Y, Wang H, Li R, Qiao J, et al., Impact of thyroid autoimmunity on in vitro fertilization/intracytoplasmic sperm injection outcomes and fetal weight. Front Endocrinol (Lausanne). 2021;12(698579. 10.3389/fendo.2021.698579 [DOI] [PMC free article] [PubMed]
- 108.Korevaar TIM, Medici M, Visser TJ, Peeters RP. Thyroid disease in pregnancy: new insights in diagnosis and clinical management. Nat Rev Endocrinol. 2017;13(10):610–22. 10.1038/nrendo.2017.93. [DOI] [PubMed] [Google Scholar]
- 109.Derakhshan A, Peeters RP, Taylor PN, Bliddal S, Carty DM, Meems M, et al. Association of maternal thyroid function with birthweight: a systematic review and individual-participant data meta-analysis. Lancet Diabetes Endocrinol. 2020;8(6):501–10. 10.1016/s2213-8587(20)30061-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 110.Zhu YD, Han Y, Huang K, Zhu BB, Yan SQ, Ge X, et al. The impact of isolated maternal hypothyroxinaemia on the incidence of large-for-gestational-age infants: the Ma’anshan birth cohort study. BJOG. 2018;125(9):1118–25. 10.1111/1471-0528.15107. [DOI] [PubMed] [Google Scholar]
- 111.Carlsen E, Lee Y, Magnus P, Jugessur A, Page CM, Nustad HE, et al. An examination of mediation by DNA methylation on birthweight differences induced by assisted reproductive technologies. Clin Epigenetics. 2022;14(1): 151. 10.1186/s13148-022-01381-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 112.Li B, Chen S, Tang N, Xiao X, Huang J, Jiang F, et al. Assisted reproduction causes reduced fetal growth associated with downregulation of paternally expressed imprinted genes that enhance fetal growth in mice. Biol Reprod. 2016;94(2):45. 10.1095/biolreprod.115.136051. [DOI] [PubMed] [Google Scholar]
- 113.Salmeri N, Carbone IF, Cavoretto PI, Farina A, Morano D. Epigenetics beyond fetal growth restriction: a comprehensive overview. Mol Diagn Ther. 2022;26(6):607–26. 10.1007/s40291-022-00611-4. [DOI] [PubMed] [Google Scholar]
- 114.Yang L, Li Z, Liu Y, Zhang JW, Wang YX, Hu JJ, et al. Influences of fresh and frozen embryo transfer on neonatal birthweight and the expression of imprinted genes PEG10 /L3MBTL1 in placenta. Reprod Biol. 2022;22(3): 100665. 10.1016/j.repbio.2022.100665. [DOI] [PubMed] [Google Scholar]
- 115.Dall’Asta A, Girardelli S, Usman S, Lawin-O’Brien A, Paramasivam G, Frusca T, et al., Etiology and perinatal outcome of periviable fetal growth restriction associated with structural or genetic anomaly. Ultrasound Obstet Gynecol. 2020;55(3):368–374. 10.1002/uog.20368 [DOI] [PubMed]
- 116.Ma Y, Lei E, Xu Y, Feng Y, Prenatal diagnosis and molecular cytogenetic characterization of inherited chromosome 2q11.1q11.2 microduplication with fetal intrauterine growth retardation. Taiwan J Obstet Gynecol. 2022;61(4):726–727. 10.1016/j.tjog.2021.12.005 [DOI] [PubMed]
- 117.Kasapkara ÇS, Tümer L, Ezgü FS, Küçükçongar A, Hasanoğlu A. BCS1L gene mutation causing GRACILE syndrome: case report. Ren Fail. 2014;36(6):953–4. 10.3109/0886022x.2014.900422. [DOI] [PubMed] [Google Scholar]
- 118.Mertens J, Belva F, van Montfoort APA, Regin M, Zambelli F, Seneca S, et al. Children born after assisted reproduction more commonly carry a mitochondrial genotype associating with low birthweight. Nat Commun. 2024;15(1):1232. 10.1038/s41467-024-45446-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 119.Hattersley AT, Tooke JE. The fetal insulin hypothesis: an alternative explanation of the association of low birthweight with diabetes and vascular disease. Lancet. 1999;353(9166):1789–92. 10.1016/s0140-6736(98)07546-1. [DOI] [PubMed] [Google Scholar]
- 120.Chang S, Bartolomei MS, Modeling human epigenetic disorders in mice: Beckwith-Wiedemann syndrome and Silver-Russell syndrome. Dis Model Mech. 2020;13(5). 10.1242/dmm.044123 [DOI] [PMC free article] [PubMed]
- 121.Wu H, Zhu P, Geng X, Liu Z, Cui L, Gao Z, et al. Genetic polymorphism of MTHFR C677T with preterm birth and low birth weight susceptibility: a meta-analysis. Arch Gynecol Obstet. 2017;295(5):1105–18. 10.1007/s00404-017-4322-z. [DOI] [PubMed] [Google Scholar]
- 122.Ashapkin V, Suvorov A, Pilsner JR, Krawetz SA, Sergeyev O. Age-associated epigenetic changes in mammalian sperm: implications for offspring health and development. Hum Reprod Update. 2023;29(1):24–44. 10.1093/humupd/dmac033. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 123.Morisaki N, Kawachi I, Oken E, Fujiwara T, Social and anthropometric factors explaining racial/ethnical differences in birth weight in the United States. Sci Rep. 2017;7(46657. 10.1038/srep46657 [DOI] [PMC free article] [PubMed]
- 124.Tang J, Zhu X, Chen Y, Huang D, Tiemeier H, Chen R, et al. Association of maternal pre-pregnancy low or increased body mass index with adverse pregnancy outcomes. Sci Rep. 2021;11(1):3831. 10.1038/s41598-021-82064-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 125.Wojtyla C, Wojtyla-Buciora P, Ciebiera M, Orzechowski S, Wojtyla A. The effect of active and passive maternal smoking before and during pregnancy on neonatal weight at birth. Arch Med Sci. 2021;17(2):352–60. 10.5114/aoms.2018.79629. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 126.Broere-Brown ZA, Baan E, Schalekamp-Timmermans S, Verburg BO, Jaddoe VW, Steegers EA, Sex-specific differences in fetal and infant growth patterns: a prospective population-based cohort study. Biol Sex Differ. 2016;7(65. 10.1186/s13293-016-0119-1 [DOI] [PMC free article] [PubMed]
- 127.Franklin P, Tan M, Hemy N, Hall GL, Maternal exposure to indoor air pollution and birth outcomes. Int J Environ Res Public Health. 2019;16(8). 10.3390/ijerph16081364 [DOI] [PMC free article] [PubMed]
- 128.Magnus MC, Wilcox AJ, Fadum EA, Gjessing HK, Opdahl S, Juliusson PB, et al. Growth in children conceived by ART. Hum Reprod. 2021;36(4):1074–82. 10.1093/humrep/deab007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 129.Hann M, Roberts SA, D’Souza SW, Clayton P, Macklon N, Brison DR. The growth of assisted reproductive treatment-conceived children from birth to 5 years: a national cohort study. BMC Med. 2018;16(1):224. 10.1186/s12916-018-1203-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 130.Yeung EH, Sundaram R, Bell EM, Druschel C, Kus C, Xie Y, et al. Infertility treatment and children’s longitudinal growth between birth and 3 years of age. Hum Reprod. 2016;31(7):1621–8. 10.1093/humrep/dew106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 131.Laugesen K, Veres K, Hernandez-Diaz S, Chiu YH, Oberg AS, Hsu J, et al. Overweight or obesity in children born after assisted reproductive technologies in Denmark: a population-based cohort study. PLoS Med. 2023;20(12): e1004324. 10.1371/journal.pmed.1004324. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 132.Elhakeem A, Taylor AE, Inskip HM, Huang J, Tafflet M, Vinther JL, et al. Association of assisted reproductive technology with offspring growth and adiposity from infancy to early adulthood. JAMA Netw Open. 2022;5(7): e2222106. 10.1001/jamanetworkopen.2022.22106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 133.Terho AM, Tiitinen A, Salo J, Martikainen H, Gissler M, Pelkonen S. Growth of singletons born after frozen embryo transfer until early adulthood: a Finnish register study. Hum Reprod. 2024;39(3):604–11. 10.1093/humrep/dead264. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 134.Hinchely Ebdrup N, Hohwü L, Bay B, Obel C, Knudsen UB, Kesmodel US. Long-term growth in offspring of infertile parents: A 20-year follow-up study. Acta Obstet Gynecol Scand. 2021;100(10):1849–57. 10.1111/aogs.14215. [DOI] [PubMed] [Google Scholar]
- 135.Terho AM, Pelkonen S, Toikkanen R, Koivurova S, Salo J, Nuojua-Huttunen S, et al. Childhood growth of term singletons born after frozen compared with fresh embryo transfer. Reprod Biomed Online. 2021;43(4):719–26. 10.1016/j.rbmo.2021.08.002. [DOI] [PubMed] [Google Scholar]
- 136.Ainsworth AJ, Wyatt MA, Shenoy CC, Hathcock M, Coddington CC. Fresh versus frozen embryo transfer has no effect on childhood weight. Fertil Steril. 2019;112(4):684–690.e1. 10.1016/j.fertnstert.2019.05.020. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Data sharing is not applicable to this manuscript, as no new datasets (human or animal) were generated or analyzed during the current study.